Charney Laurence N sold $275K of TGTX

TG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.

Simply Wall St reports TG Therapeutics (TGTX) posted Q2 2026 revenue of $240.34 million versus $141.15 million a year earlier, while net income fell to $7.78 million from $28.19 million. The company raised full-year 2026 total global revenue guidance to about $950 million, citing improved commercial trajectory.

TG Therapeutics (TGTX) reported Q2 2026 results with higher revenue and lower net income, and raised full-year revenue guidance to about $950 million, according to the company. The stock last traded at $47.94, framed by Simply Wall St as modestly undervalued versus a $51.71 fair value, largely tied to BRIUMVI ramp-up and market access.

TG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.

TG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.

TG Therapeutics Inc. (TGTX) reported Q2 net income of $7.8 million, or 5 cents per share, below Wall Street expectations of 41 cents per share, according to Zacks. Revenue was $240.3 million, above the $230.9 million forecast. The company expects full-year revenue of $950 million.